Clinical Trial Update: BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

View source ↗

Summary

A completed clinical trial investigated BRAF V600E–driven redifferentiation therapy for radioiodine-refractory papillary thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Thyroid Cancer
• Thyroid Cancer

Snippet

Sponsor: Heidelberg University | Conditions: Thyroid Cancer | Status: COMPLETED